Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 13/20 | 0.47 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 6/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25616467 | 1.00 | BTK (0.47) | BTKTNK2EGFRIGF1R | |
| SCHEMBL25271079 | 0.95 | BTK (0.48) | BTKTNK2EGFRIGF1R | |
| SCHEMBL25223658 | 0.95 | BTK (0.48) | BTKTNK2EGFRIGF1R | |
| SCHEMBL25618084 | 0.93 | BTK (0.48) | BTKTNK2EGFR | |
| SCHEMBL25273607 | 0.93 | BTK (0.47) | BTKTNK2EGFR | |
| SCHEMBL25230880 | 0.93 | BTK (0.47) | BTKTNK2EGFR | |
| SCHEMBL25269359 | 0.92 | BTK (0.48) | BTKTNK2EGFR | |
| SCHEMBL25269360 | 0.92 | BTK (0.48) | BTKTNK2EGFR | |
| SCHEMBL25274984 | 0.92 | BTK (0.46) | BTKTNK2EGFR | |
| SCHEMBL25274983 | 0.92 | BTK (0.46) | BTKTNK2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BEIJING INNOCARE PHARMA TECH CO LTD (CN) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192691-A1 | HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS | BTK, SYK, LYN | BTK 1/4885TNK2 133/4885EGFR 311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.